http://www.msnbc.com/news/935882.asp?0na=x2203111B

New device can manage diabetes

Associated Press

Some diabetics will no longer have to add up how much insulin they need for
every bite of food. The Food and Drug Administration on Monday approved the
first device that checks a patient's blood sugar, automatically calculates how
much insulin they need and signals an implanted pump to send out the right dose.

THE PARADIGM SYSTEM is a first step toward developing an artificial pancreas.

Diabetes specialists hope the new device will cut down on dosing errors and make
it easier for patients to manage their disease.

"The smarter these systems can become ... the better our patients ought to be
able to do," said American Diabetes Association past president Francine Kaufman,
a pediatric endocrinologist at Children's Hospital of Los Angeles.

Diabetes is a leading cause of blindness, kidney failure and amputations, and
dramatically raises the risk of heart attacks. It kills 180,000 Americans each
year.

Some diabetics control their disease with diet, exercise and various
medications; others require regular injections of insulin, a hormone crucial to
converting blood sugar into energy.

More than 200,000 diabetics have insulin pumps implanted in their abdomens, a
programmable system that can provide more precise, regular doses, infusing even
while the patient is sleeping.

Patients still must figure out how much and when their pumps should emit by
pricking their fingers to see how much glucose is in their blood and calculating
how many carbohydrates they plan to eat. Calculating wrong could cause
dangerously high or low doses.

The new system combines a Medtronic MiniMed Inc. insulin pump with a glucose
monitor from Becton Dickinson to do a lot of that work automatically.

Patients still will prick their fingers, but the pager-sized monitor uses
wireless technology to beam the glucose reading straight to the implanted
insulin pump.

Once meal plans are punched in, a calculator in the pump will deliver a dose
recommendation by calculating target glucose levels, the patient's insulin
sensitivity and how much insulin already is in the blood.

The patient still has final control, and may override the recommended dose.

Medtronic said the prescription-only device will begin shipping July 21 and cost
$5,995, $500 more than Medtronic's manually programmed insulin pump.

Shares in Medtronic rose 18 cents to $47.73 each on the New York Stock Exchange,
where Becton Dickinson shares rose 24 cents to $39.75.

© 2003 Associated Press. All rights reserved. This material may not be
published, broadcast, rewritten or redistributed.

MSNBC Terms, Conditions and Privacy ©2003






Yerachmiel Bruchya haLevi Altman


[Non-text portions of this message have been removed]